HC Wainwright Issues Positive Estimate for INO Earnings

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Stock analysts at HC Wainwright raised their Q1 2025 earnings estimates for shares of Inovio Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will earn ($0.75) per share for the quarter, up from their prior forecast of ($0.78). HC Wainwright currently has a “Neutral” rating and a $3.00 target price on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.43) EPS and FY2025 earnings at ($2.12) EPS.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.18. The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.03 million.

INO has been the topic of several other research reports. Royal Bank of Canada reduced their target price on shares of Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating on the stock in a report on Wednesday. StockNews.com raised shares of Inovio Pharmaceuticals to a “sell” rating in a report on Friday. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 target price on shares of Inovio Pharmaceuticals in a research report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Inovio Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $12.20.

Inovio Pharmaceuticals Stock Performance

INO stock opened at $1.92 on Friday. Inovio Pharmaceuticals has a 52 week low of $1.74 and a 52 week high of $14.75. The firm’s fifty day moving average is $2.04 and its 200 day moving average is $3.71. The firm has a market cap of $50.11 million, a P/E ratio of -0.91 and a beta of 0.92.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets lifted its position in Inovio Pharmaceuticals by 177.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 3,630 shares during the period. MetLife Investment Management LLC grew its position in Inovio Pharmaceuticals by 129.1% during the third quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 8,546 shares during the period. Alpine Global Management LLC bought a new stake in Inovio Pharmaceuticals during the fourth quarter valued at approximately $31,000. Atom Investors LP purchased a new position in Inovio Pharmaceuticals during the third quarter valued at approximately $103,000. Finally, Bank of Montreal Can purchased a new position in Inovio Pharmaceuticals during the fourth quarter valued at approximately $43,000. 26.79% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.